08:00 AM EDT, 07/01/2024 (MT Newswires) -- Gene therapy manufacturer Genezen said Monday it will acquire uniQure's (QURE) commercial gene therapy operations in Lexington, Massachusetts.

Under the agreement, Genezen said it will sign supply agreements for uniQure's clinical portfolio and Hemgenix, uniQure's gene therapy for hemophilia B.

Hemgenix, which is commercialized by CSL Behring, is manufactured at the Lexington facility.

Financial details of the deal were not disclosed.

Shares of the company were up 4.2% in recent Monday premarket activity.

Price: 4.6700, Change: +0.19, Percent Change: +4.24